Phil Borman

Dr. Phil Borman

GSK
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
PJPatrick Jackson
Patrick Jackson
PBPhil Borman
Phil Borman
CCCristiana Campa
Cristiana Campa
MCMarion J Chatfield
Marion J Chatfield
MGMark Godfrey
Mark Godfrey
TSTimothy Schofield
Timothy Schofield

24 May 2005 in Analytical Chemistry
Verified
Journal Article
Closed access
SLSteve Lane
Steve Lane
BBBob Boughtflower
Bob Boughtflower
IMIan Mutton
Ian Mutton
CPClare Paterson
Clare Paterson
DFDuncan Farrant
Duncan Farrant
PBPhil Borman
Phil Borman

20 December 2021 in Analytical Chemistry
Verified
Journal Article
Open access
PBPhil Borman
Phil Borman
CCCristiana Campa
Cristiana Campa
GDGhislain Delpierre
Ghislain Delpierre
EHElliot Hook
Elliot Hook
PJPatrick Jackson
Patrick Jackson
OVOlivier Vandeputte
Olivier Vandeputte
A structured approach to method development can help to ensure an analytical procedure is robust across the lifecycle of its use. The analytical target profile (ATP), which describes the required quality of the reportable value to be produced by the analytical procedure, enables the analytical scientist to select the best analytical technology on which to develop their procedure(s). Once the technology has been identified, screening of potentially fit for purpose analytical procedures should take place. Analytical procedures that have been demonstrated to meet the ATP should be evaluated against business drivers (e.g., operational constraints) to determine the most suitable analytical procedure. Three case studies are covered from across small molecules, vaccines, and biotherapeutics. The case studies cover different aspects of the analytical procedure selection process, such as the use of platform method development processes and procedures, the development of multiattribute analytical procedures, and the use of analytical technologies to provide product characterization knowledge in order to define or redefine the ATP. Challenges associated with method selection are discussed such as where existing pharmacopoeial monographs link acceptance criteria to specific types of analytical technology.

19 November 2009 in Analytical Chemistry
Verified
Journal Article
Closed access
PBPhil Borman
Phil Borman
MCMarion J. Chatfield
Marion J. Chatfield
IDIvana Damjanov
Ivana Damjanov
PJPatrick Jackson
Patrick Jackson

12 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JAJuan Carlos Zelaya Almeida
Juan Carlos Zelaya Almeida
MBMariana Bezerra
Mariana Bezerra
DMDaniel Markl
Daniel Markl
ABAndreas Berghaus
Andreas Berghaus
PBPhil Borman
Phil Borman
Walkiria SchlindweinWalkiria Schlindwein
Walkiria Schlindwein
A key principle of developing a new medicine is that quality should be built in, with a thorough understanding of the product and the manufacturing process supported by appropriate process controls. Quality by design principles that have been established for the development of drug products/substances can equally be applied to the development of analytical procedures. This paper presents the development and validation of a quantitative method to predict the concentration of piroxicam in Kollidon® VA 64 during hot melt extrusion using analytical quality by design principles. An analytical target profile was established for the piroxicam content and a novel in-line analytical procedure was developed using predictive models based on UV-Vis absorbance spectra collected during hot melt extrusion. Risks that impact the ability of the analytical procedure to measure piroxicam consistently were assessed using failure mode and effect analysis. The critical analytical attributes measured were colour (L* lightness, b* yellow to blue colour parameters—in-process critical quality attributes) that are linked to the ability to measure the API content and transmittance. The method validation was based on the accuracy profile strategy and ICH Q2(R1) validation criteria. The accuracy profile obtained with two validation sets showed that the 95% β-expectation tolerance limits for all piroxicam concentration levels analysed were within the combined trueness and precision acceptance limits set at ±5%. The method robustness was tested by evaluating the effects of screw speed (150–250 rpm) and feed rate (5–9 g/min) on piroxicam content around 15% w/w. In-line UV-Vis spectroscopy was shown to be a robust and practical PAT tool for monitoring the piroxicam content, a critical quality attribute in a pharmaceutical HME process.

19 November 2009 in Analytical Chemistry
Verified
Journal Article
Closed access
MCMarion J. Chatfield
Marion J. Chatfield
PBPhil Borman
Phil Borman